Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $448.3 million.

  • Centessa Pharmaceuticals' Liabilities and Shareholders Equity fell 2647.38% to $448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 2051.25%. This contributed to the annual value of $576.8 million for FY2024, which is 6011.23% up from last year.
  • Per Centessa Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $448.3 million for Q3 2025, which was down 2647.38% from $492.1 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $609.7 million during Q3 2024, and its lowest value of $328.2 million during Q1 2024.
  • In the last 4 years, Centessa Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $448.3 million in 2025 and averaged $462.9 million.
  • In the last 5 years, Centessa Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 3063.07% in 2023 and then soared by 6157.21% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' Liabilities and Shareholders Equity stood at $444.3 million in 2022, then decreased by 18.92% to $360.2 million in 2023, then surged by 60.11% to $576.8 million in 2024, then fell by 22.28% to $448.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $448.3 million for Q3 2025, versus $492.1 million for Q2 2025 and $527.8 million for Q1 2025.